Company Overview
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of novel synthetic lethality-based cancer therapeutics that specifically target DNA damage response pathways. The company functions within the Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized player focused on advancing innovative oncology treatments through molecular inhibition strategies. Currently, the firm employs eight individuals and holds a market capitalization of $7.82M, while reporting a trailing twelve-month revenue of $285,759. These valuation and revenue figures indicate that Aprea Therapeutics is an early-stage micro-cap biotechnology firm with a very small operational footprint, reflecting the typical resource constraints and high-risk profile associated with companies in the clinical development phase that have not yet achieved significant commercial scale.
Financial Health
The company reported a revenue of $285,759 over the trailing twelve months, yet recorded a net income of $-12,599,569 and an EBITDA of $-13,212,121, revealing a substantial gap between top-line generation and bottom-line profitability that underscores a cost structure dominated by research, development, and operational expenses typical of pre-revenue biotech ventures. Free cash flow stands at $-8,564,504, which signifies that the company is consuming cash reserves to fund its operations and product development rather than generating excess liquidity for distribution or debt reduction. The gross margin is listed at 0.0%, the operating margin is -79205.7%, and the profit margin is 0.0%; these figures collectively indicate that the company is not yet generating positive profitability from its sales or operations, a common characteristic for clinical-stage entities before reaching commercial thresholds. Regarding leverage, the company holds $14.60M in cash against no reported debt, resulting in a debt-to-equity ratio of N/A, which suggests a conservative balance sheet where the firm relies entirely on equity and cash reserves to finance its activities without taking on significant financial obligations. The current ratio is 5.63, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer to meet immediate financial obligations. Furthermore, the Return on Equity is -74.6% and the Return on Assets is -41.4%, metrics that reveal management is currently utilizing the company's capital base to generate losses rather than returns, a status expected during the heavy investment phases of biotechnology research and clinical trials.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is -1.03, a disparity that implies earnings are currently negative and future earnings projections are insufficient to support a traditional positive multiple, necessitating reliance on alternative valuation frameworks for clinical-stage assets. The price-to-book ratio is 0.45, which indicates that the market values the company at less than its book value, suggesting that investors are pricing the firm based on its tangible assets or potential downside risk rather than a premium for intangible intellectual property or growth prospects. The price-to-sales ratio is 27.37 and the EV/EBITDA is 0.46; these alternative metrics suggest that while the company commands a high multiple relative to its minimal sales due to its clinical pipeline potential, its enterprise value relative to earnings is compressed because of the significant accumulated losses. The stock has traded within a 52-week range between a high of $2.42 and a low of $0.55, meaning the current valuation sits below the recent peak but above the recent trough, reflecting the volatility inherent in small-cap biotechnology equities. The beta is 1.55, which means the stock price exhibits higher volatility relative to the broader market, rising and falling more sharply than the general market index during periods of price fluctuation.
Growth & Income
Revenue growth year-over-year is -98.4% and earnings growth is N/A, indicating that the company has experienced a drastic contraction in reported revenue and is currently in a phase where earnings are negative rather than positive, implying that the business model is transitioning from earlier stages of operation or restructuring its revenue recognition. For dividend purposes, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders and retains all available cash to fund its operations and development pipeline. As a non-dividend payer, Aprea Therapeutics reinvests its earnings—which are currently negative—into growth initiatives rather than paying out income, a standard practice for early-stage biotech firms seeking to extend their runway. Overall, the growth and income profile is characterized by significant revenue decline, zero dividend distribution, and a reliance on internal cash reserves to sustain operations in the absence of profitable earnings or external equity financing.